Novo Nordisk A/S (NYSE:NVO) Issues Quarterly Earnings Results

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings results on Wednesday. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03, Zacks reports. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. Novo Nordisk A/S updated its FY 2025 guidance to EPS.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $85.83 on Thursday. The firm has a market capitalization of $385.16 billion, a PE ratio of 27.78, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The firm has a 50-day moving average price of $92.65 and a 200 day moving average price of $112.19.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.